Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2021 Feb 11;16(2):e0246416. doi: 10.1371/journal.pone.0246416

Meta-analysis of the correlation between serum uric acid level and carotid intima-media thickness

Mingzhu Ma 1,#, Liangxu Wang 2,#, Wenjing Huang 1, Xiaoni Zhong 1, Longfei Li 1, Huan Wang 3, Bin Peng 1, Min Mao 4,*
Editor: Giuseppina Novo5
PMCID: PMC7877574  PMID: 33571245

Abstract

Objective

Recently, increasing epidemiological evidence has shown that there is a correlation between serum uric acid level (SUA) and carotid intima-media thickness (CIMT). This paper explored the relationship between them through meta-analysis.

Methods

PubMed, Cochrane Library, EMBASE, Web of Science and Google Scholar were searched to obtain literature. The keywords used to retrieve the literature were carotid intima thickness, intima-media thickness, carotid atherosclerosis, carotid stenosis, carotid artery, uric acid, blood uric acid, and hyperuricaemia. The retrieval time was from the establishment of the database through July 2020. Stata15.0 and RevMan5.3 software were used for statistical analysis. The standardized mean difference (SMD) and 95% confidence interval (95% CI) were calculated by a random effect model to estimate the correlation. Publication bias was assessed using the Begg and Egger tests. The stability of these results was evaluated using sensitivity analyses.

Results

Fifteen studies were included with a total sample size of 11382, including 7597 participants in the high uric acid group and 3785 in the control group, on the basis of the inclusion and exclusion criteria. According to the evaluation of the JBI scale, the literature was of high quality. The average age ranged from 42 to 74. Meta-analysis showed that CIMT in the high uric acid group was significantly higher than that in the control group (SMD = 0.53, 95% CI: [0.38, 0.68]), and the difference was significant (z = 6.98, P < 0.00001). The heterogeneity among the 15 articles was obvious (I2 = 89%, P < 0.00001). Subgroup analysis by disease status illustrated a positive relationship between SUA and CIMT in healthy people and people with diseases. SUA was shown to be positively correlated with CIMT in people aged 45–60 years and ≥60 years by subgroup analysis by age. SUA was also found to be positively correlated with CIMT in a population with BMI>24 kg/m2 by subgroup analysis by BMI. In addition, subgroup analysis of other risk factors for CIMT, including TC, SBP, DBP, triglycerides, and LDL-C, all showed a positive correlation between SUA and CIMT.

Conclusions

There is a significant correlation between serum uric acid level and carotid intima-media thickness, and a high concentration of serum uric acid is related to carotid artery intima-media thickness.

Introduction

Hyperuricaemia is a disorder caused by the dysfunction of purine metabolism. When the level of uric acid in the human body is imbalanced, synthesis is reduced, and hyperuricaemia occurs. Hyperuricaemia affects blood vessels, limbs and joints and damages many important organs in the human body, and it is an important biochemical basis of gout. Gout can lead to kidney stones, uric acid nephropathy and even renal failure. With substantial changes in the traditional lifestyle, the consumption of high purine and high protein foods has increased, and hyperuricaemia has become a common clinical disease. The incidence of hyperuricaemia has shown a significant upward trend in recent years [13]. The prevalence of hyperuricaemia and gout in mainland China from 2000 to 2014 was 13.3% and 1.1%, respectively [4]. In a nationally representative sample of U.S. adults, the prevalence of gout and hyperuricaemia remained high from 2007 to 2016. In 2015–2016, the prevalence of gout in adults in the United States was 3.9% (9.2 million), with 5.2% (5.9 million) in men and 2.7% (3.3 million) in women. The prevalence of hyperuricaemia was 20.2% and 20.0%, respectively [5].

The prevalence of atherosclerotic cardiovascular disease (ASCVD) is increasing and has become the leading cause of death and disability worldwide [6], with significant negative impacts on individuals, families and societies. Both the heart and brain exhibit similar vascular anatomy, with large ductal arteries extending from the surface of the organs and providing tissue perfusion through a complex network of small vessels. Both organs rely on fine-tuning of local blood flow to meet metabolic demands [7]. Atherosclerosis is the common pathological basis of cardiovascular and cerebrovascular diseases, and there is a strong correlation between carotid atherosclerosis and cardiovascular and cerebrovascular diseases. Carotid intimal thickening is considered to be an objective indicator of early atherosclerosis and an effective predictor of systemic atherosclerosis, which is closely related to the occurrence of coronary heart disease and ischaemic stroke [8].

At present, the relationship between serum uric acid level and carotid intima-media thickness has become a research hotspot, but the research results are controversial. A number of studies have found that the serum uric acid level is independently related to CIMT thickening [9, 10], but some scholars have concluded that there is no significant correlation between SUA level and IMT values in men or women [1114]. These studies indicated that whether serum uric acid levels can be considered an independent risk factor for carotid atherosclerosis remains highly controversial [15]. In conclusion, the relationship between serum uric acid levels and carotid intimal thickness is not completely clear, and there is a lack of large-sample comprehensive and systematic research. Therefore, we carried out a meta-analysis through a series of literature searches and performed a comprehensive evaluation of the relationship between the two factors by using standardized mean difference (SMD) to provide supporting evidence for further related research.

Materials and methods

Literature retrieval strategy

According to the guidelines of Preferred Reporting Items in Systematic Reviews and Meta-Analyses (PRISMA) (moher 113 et al. 2015 [16]), PubMed, Cochrane Library, EMBASE, Google Scholar and Web of Science were searched. The retrieval time was from the establishment of the database through July 2020. The following keywords were used in the retrieval process: carotid intima thickness, intima-media thickness, carotid atherosclerosis, carotid stenosis, carotid artery, uric acid, blood uric acid, and hyperuricaemia. There were no restrictions on language or region. To prevent the omission of retrieval, the titles and abstracts of the references were read and screened.

Inclusion and exclusion criteria

According to the purpose of this study, first, all published studies on the relationship between serum uric acid level and carotid intimal thickness were included, and the following inclusion and exclusion criteria were used. The inclusion criteria were (1) specific sample size values; (2) complete demographic data; (3) division of subjects into a high uric acid group and control group according to uric acid level; and (4) measurement of the CIMT. The exclusion criteria were (1) no control group; (2) missing data; (3) no specific CIMT value; (4) duplicate publication; and (5) lectures and review articles.

Data extraction and quality assessment

Literature inclusion and data extraction were conducted independently by two researchers (Mingzhu Ma and Liangxu Wang). When the results were inconsistent, experienced researchers were consulted to discuss the final results. The data extraction table includes the following contents: (1) basic characteristics of the article, including author, year, region, average age of research population, and confounding factors; and (2) effect-related data, such as sample size, mean value, and standard deviation of the high uric acid group and control group. The JBI scale was used to evaluate the quality of the studies. The scale was developed by the Joanna Evidence-based Nursing Center (JBI) in Australia. There are 10 items in the scale, and the evaluation criteria are divided into three levels: 0 points–not in accordance with the standard; 1 point–mentioned but did not provide a detailed description; and 2 points–provided a detailed, comprehensive and correct description. Articles with scores greater than 14 can be regarded as high-quality research.

Statistical analysis

Due to differences in research design between studies, the data extracted from the original studies were appropriately transformed before analysis [17]: (1) for studies that classified the participants into a high uric acid group and a control group, the extracted data were used for estimation without conversion; (2) for studies dividing the participants into multiple groups (or more than two groups), according to the definition criteria of hyperuricaemia [18], individuals meeting these standards were categorised into the high uric acid group, and the rest composed the control group; (3) hyperuricaemia was defined as > 7 mg/dl (416 μmol/L) for men and > 6 mg/dl for women, and the included studies were not grouped according to sex. We adopted the lower female criteria (> 6 mg/dl) as the cut-off for grouping. The calculation method of the mean value and standard deviation after combination is as follows [19]: supposing that the mean value and standard deviation of each group before combination are X¯T and SDT, respectively, then the combined mean and standard deviation are xT¯=i=1mnixi¯i=1mni and SDT=i=1m(ni1)SDi2+i=1mni(xi¯xT¯)2(i=1mni1). Since the measurement methods and units of CIMT in different studies are not exactly the same, the effect value SMD was used to eliminate the influence of differences. The random effects model was selected in the analysis. Heterogeneity between studies was assessed using forest plots, Q tests, and I2. The critical value of the Q-test was set at 0.1, and heterogeneity was considered obvious when I2 > 50%. Publication bias was initially judged by forest plot symmetry, and then the Begg rank correlation test and Egger’s test were performed. There was no publication bias when z < 1.96, P > 0.05 in the Begg test, and P > 0.05 with the 95% CI including 0 in the Egger test. Sensitivity analysis was used to determine the individual impact of each study on the combined results. Stata15.0 and RevMan5.3 software were used for the above analysis, and the literature quality score figure was created with R3.6.3.

Results

Literature screening process

A total of 453 studies were initially retrieved (including those identified by browsing the references of the preliminarily screened literature by the literature tracking method to make up for the possible omission of computer retrieval). Duplicate publications, lectures and review articles (n = 58), as well as articles that were not relevant to the subject and did not meet the inclusion criteria (n = 256), were excluded. The remaining 139 studies were screened after reading the full text, and 15 studies were included in the meta-analysis [2034]. The specific process is shown in Fig 1.

Fig 1. Literature screening process.

Fig 1

Basic characteristics and quality evaluation of the literature

A total of 15 articles were included in this meta-analysis, with a total sample size of 11382, including 7597 participants in the high uric acid group and 3785 participants in the control group. The study with the largest sample size included 5294 subjects (Zhang Hailing, 2016, Hebei, China), and the smallest included 80 (Yusuf Tavil, 2017, Turkey). The average age ranged from 42 to 74. In addition to healthy middle-aged and elderly people, the study population included people with type 2 diabetes, ischaemic stroke, hypertension, renal transplant, cardiac syndrome X and metabolic syndrome. The basic characteristics of the literature are shown in Table 1, and the detailed characteristics are shown in S1 Table. The quality scores of each study were evaluated by two researchers according to the 10 items of the JBI scale. When there were inconsistencies, experienced researchers were consulted. After discussion and agreement, the final data were entered. The results showed that the total score of all studies was 14 or above, and the quality of the literature was high (see Fig 2).

Table 1. Basic characteristics of included literatures.

N Author Year Region Sample size CIMT(mm) Average age Population prevalence
High uric acid group Control group High uric acid group Control group
1 Ranran Zhang[20] 2018 Qingdao, China 234 100 1.06±0.26 1.01±0.24 59.5
2 Hailing Zhang[21] 2016 Hebei, China 4739 555 0.93±0.19 0.84±0.19 55.0
3 Zhigai Zhang[22] 2013 Henan, China 54 54 1.05±0.28 0.84±0.19 52.5 Type 2 diabetes
4 Chunyu Yang[23] 2005 Guangdong, China 41 67 0.99±0.18 0.94±0.17 --
5 Francesco Antonini-Canterin[24] 2019 Italy 136 562 0.97±0.22 0.94±0.18 57.3
6 Qin Li[25] 2011 Shanghai, China 513 513 0.895±0.27 0.94±0.22 65.6 Type 2 diabetes
7 Chun-Chin Chang[26] 2018 Taiwan, China 660 313 0.675±0.135 0.94±0.11 61.7
8 Kumral.E[27] 2013 Turkey 75 331 0.9±0.3 0.94±0.2 66.0 Ischemic stroke
9 Young Seok Cho[13] 2018 Korean 505 465 0.66±0.14 0.65±0.14 52.7
10 Ryuichi Kawamoto[28] 2005 Japan 308 611 1.07±0.23 1.00±0.22 74.3
11 Mustafa Caliskan[29] 2014 Turkey 114 38 0.58±0.09 0.52±0.09 44.6 Masked hypertension
12 E.Asicioglu[30] 2014 Turkey 46 44 0.58±0.09 0.57±0.1 41.5 Renal Transplant
13 Nusret Acikgoz[31] 2011 Turkey 50 40 0.75±0.18 0.63±0.09 51.8 Cardiac Syndrome X
14 Yusuf Tavil[32] 2007 Turkey 55 25 0.76±0.15 0.57±0.16 50.3 Hypertension
15 Shun-Sheng Wu[33] 2019 Taiwan, China 67 67 0.75±0.11 0.66±0.1 50.8 Metabolic Syndrome

Fig 2. Quality score of literature.

Fig 2

(a) The thermal map of quality scores: 1–15 represents the 15 studies included, 1)-10) represents the 10 evaluation items. (b) Bar chart of the score distribution of each item.

Meta-analysis results

The results of the combined analysis of the random effect model showed that the CIMT value of the high uric acid group was significantly higher than that of the control group (SMD = 0.50, 95% CI = [0.34, 0.66]), and the difference was statistically significant (z = 6.24, P < 0.00001) (Table 2). There was significant heterogeneity among the 15 included studies (I2 = 89%, P < 0.00001) (Table 3). The forest plot is shown in Fig 3.

Table 2. Overall and subgroup analysis of the correlation between SUA and CIMT.

Number SMD 95% CI z P
Overall 15 0.50 [0.34,0.66] 6.24 <0.00001
Population prevalence
    Healthy people 7 0.29 [0.17,0.42] 4.55 <0.00001
    People with diseases 8 0.73 [0.52,0.95] 6.59 <0.00001
Age
18–45 2 0.39 [-0.16,0.94] 1.4 0.16
45–60 8 0.53 [0.32,0.75] 4.85 <0.00001
≥60 4 0.52 [0.19,0.84] 3.09 0.002
BMI (kg/m2)
≤24 2 0.74 [-0.16,1.63] 1.61 0.11
>24 8 0.52 [0.28,0.76] 4.29 <0.0001
TC (mmol/L)
<5.2 7 0.45 [0.29,0.61] 5.57 <0.00001
≥5.2 5 0.70 [0.37,1.04] 4.09 <0.0001
SBP (mmhg)
<140 7 0.44 [0.27,0.61] 5.10 <0.00001
≥140 3 0.80 [0.29,1.30] 3.08 0.002
DBP (mmhg)
<90 8 0.53 [0.30,0.76] 4.57 <0.00001
≥90 1 1.23 [0.72,1.74] 4.71 <0.00001
Triglyceride(mmol/L)
<1.7 9 0.46 [0.28,0.64] 4.98 <0.00001
≥1.7 1 0.94 [0.81,1.07] 14.29 <0.00001
LDL-C(mmol/L)
<3.4 8 0.51 [0.25,0.76] 3.84 0.0001
≥3.4 1 1.23 [0.72,1.74] 4.71 <0.00001

Note: (a) SMD, standardized mean difference; 95% CI, 95% confidence interval; z, significance test for SMD = 0; (b) TC, total cholesterol; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.

Table 3. Heterogeneity test of the included literature and subgroups.

Number Chi2 P I2
All literature 15 128.08 <0.00001 89%
Population prevalence
    Healthy people 7 27.80 0.0001 78%
    People with diseases 8 26.21 0.0005 73%
Age
18–45 2 3.85 0.05 74%
45–60 8 57.21 <0.00001 88%
≥60 4 55.32 <0.00001 95%
BMI (Kg/m2)
≤24 2 11.48 0.0007 91%
>24 8 103.29 <0.00001 93%
TC (mmol/L)
<5.2 7 19.12 0.004 69%
≥5.2 5 55.69 <0.00001 93%
SBP (mmhg)
<140 7 40.95 <0.00001 85%
≥140 3 31.97 <0.00001 94%
DBP (mmhg)
<90 8 104.84 <0.00001 93%
≥90 1 - - -
Triglyceride(mmol/L)
<1.7 9 45 <0.00001 82%
≥1.7 1 - - -
LDL-C(mmol/L)
<3.4 8 109.02 <0.00001 94%
≥3.4 1 - - -

Note: chi2 represents the chi square value in the Q test.

Fig 3. Overall forest plot of the meta-analysis on the association between SUA and CIMT.

Fig 3

Because the correlation between SUA and CIMT is affected by population characteristics and may be affected by other risk factors for CIMT, we conducted subgroup analyses. Initially, we divided the population into two groups and found that CIMT levels were higher in the high uric acid group than in the control group, both in healthy people and in people with diseases. (Healthy people: SMD = 0.29, 95% CI: [0.17, 0.42]; people with diseases: SMD = 0.73, 95% CI: [0.52, 0.95]). The differences were statistically significant (P < 0.00001), as shown in Fig 4, which meant that SUA levels were positively correlated with CIMT. In addition, the heterogeneity of the two subgroups decreased but was still significant (I2 = 78%, P = 0.0001; I2 = 73%, P = 0.0005).

Fig 4. Subgroup analysis of forest plot based on population prevalence, age, and BMI.

Fig 4

To further control for confounders, we performed an age-based subgroup analysis and found a positive correlation between SUA and CIMT in people aged 45–60 years and ≥60 years (Fig 4), but no correlation was found in people between the ages of 18 and 45. We also performed a subgroup analysis based on BMI. The SUA level was significantly positively correlated with CIMT in people with BMI>24 kg/m2. In addition, we performed subgroup analysis on other risk factors for CIMT: TC, SBP, DBP, triglycerides and LDL-C (the forest plots are shown in S1 Appendix). The results showed that the carotid intimal thickness of the high uric acid group was higher than that of the control group, and the difference was statistically significant (Table 2). The heterogeneity of each subgroup is shown in Table 3.

Publication bias and sensitivity analysis

To measure publication bias, a forest plot was drawn. The distribution on both sides of the graph is approximately symmetrical (Fig 5). The results of Begg’s and Egger’s tests showed that there was no significant publication bias among the articles included in this meta-analysis. (Begg: z = 1.39, P = 0.166; Egger: P = 0.530, 95% CI: [- 2.450, 4.536]). One study at a time was removed from the total combined results to explore the impact of the study on the overall SMD. The results showed that the combined values of the remaining research exhibited no significant differences compared with the original combined values (Fig 6). The sensitivity analysis showed the stability of the results.

Fig 5. Publication bias analysis.

Fig 5

Fig 6. Sensitivity analysis.

Fig 6

Discussion

Carotid intima-media thickness is associated with the degree of coronary atherosclerosis and the outcome of ischaemic stroke and has been used as an alternative marker for cardiovascular and cerebrovascular diseases in clinical trials and observational studies [3437]. The destruction of the vascular wall and endothelial cell function are direct causes of atherosclerosis. As an end product of purine metabolism in humans and higher primates, uric acid can damage the integrity of the vascular surface and affect the function of endothelial cells through direct or indirect effects on the vascular endothelium. The mechanism of this process is as follows: uric acid can promote the proliferation and migration of vascular smooth muscle cells and even lead to vascular remodelling, affecting its normal function. When the concentration of uric acid in the blood reaches a certain level, it will deposit into the tissue in the form of urate crystals and damage the vascular endothelium. The occurrence of hyperuricaemia aggravates abnormalities in metabolites and affects the vascular endothelium and haemodynamics [20]. Oxidative stress is the key link in endothelial dysfunction caused by hyperuricaemia and is related to the increased risk of cardiovascular and cerebrovascular disease [38].

Because uric acid is generally considered to have more harmful than protective effects, it is considered to be a risk factor for CIMT and atherosclerosis [35, 36, 33], but the clinical relevance of the two has been controversial. Since 1950, research on the relationship between serum uric acid level and carotid intima-media thickness has attracted scholars’ attention [39]. In a family-based study, 449 members of 107 families were analysed, and the results showed that SUA plays an important regulatory role in atherosclerosis [40]. Another cross-sectional study of 8144 healthy people reached the same conclusion and noted that SUA is an independent risk factor for atherosclerotic plaque [41]. In contrast, some studies have shown that serum uric acid levels are not an independent risk factor for cardiovascular and cerebrovascular diseases and atherosclerosis. A cohort study based on rural communities found that serum uric acid level was a risk factor for arterial stiffness but was not associated with carotid intimal thickness [12].

As the level of serum uric acid in adults will be affected by many factors, other risk factors for cardiovascular and cerebrovascular diseases, such as hypertension, diabetes, metabolic syndrome, smoking, alcohol consumption, etc., will have an impact on it [26]. In people with multiple diseases, the relationship between SUA and atherosclerosis is likely to be influenced by other cardiovascular and cerebrovascular risk factors [42]. In previous studies, when clarifying the role of serum uric acid levels in cardiovascular disease, the results were greatly limited by the single research population [26], which made it difficult to explain this debate. Therefore, it is important to carry out systematic large-sample studies involving various populations.

In this paper, we systematically reviewed the published studies on the relationship between uric acid concentration and carotid intimal thickness through a meta-analysis. In addition to healthy people, the study population included participants with type 2 diabetes, hypertension, ischaemic stroke, renal transplant and metabolic syndrome. Meta-analysis showed that there was a significant correlation between SUA and CIMT. To exclude the deviation caused by population differences, the population was divided into groups according to the disease situation through subgroup analysis. We found that increased uric acid levels were associated with carotid intimal thickening in both healthy individuals and those at high risk for cardiovascular diseases such as type 2 diabetes, hypertension, and metabolic syndrome. In addition, subgroup analysis of other risk factors for cardiovascular and cerebrovascular diseases, including age, BMI, TC, SBP, DBP, LDL-C and triglycerides, found that the correlation between SUA and CIMT was affected by other factors, but the correlation was still established. Therefore, this study revealed that a high level of SUA may be a predictor of atherosclerosis, and strengthening the control of serum uric acid levels in early prevention is helpful to reduce the risk of atherosclerosis. These findings proved that the rising level of SUA could pose an increased risk of cardiovascular and cerebrovascular diseases, provided a potential therapeutic target and new ideas for further clinical researches. It was suggested that decreasing level of uric acid could be an adjunctive therapy for cardiovascular and cerebrovascular diseases, and the atherosclerosis diagnosis and treatment also could be supported by testing the level of SUA in clinic.

There was strong heterogeneity among the 15 articles. Considering that there are differences in the correlation between SUA and CIMT among different populations and combined with the forest plot, it is preliminarily estimated that the heterogeneity comes from the study population. By removing each study one by one and calculating the heterogeneity among the remaining studies, we found that the population differences were likely to be the cause of the high heterogeneity. In the 6 studies by Zhigai Zhang 2013 [22], Qin Li 2011 [25], Mustafa Caliskan 2017 [29], Nusret Acikgoz 2011 [31], Yusuf Tavil 2007 [32], and Shun-Sheng Wu 2019 [33], study subjects had type 2 diabetes, hypertension, cardiac syndrome X, and metabolic syndrome (no renal disease or disability), and heterogeneity disappeared when subgroup analysis was performed in these six studies.

There are some limitations in this study. First, the study failed to explore differences in correlation between men and women because most of the included literature failed to group by sex. Second, similarly, different conditions of CIMT (thickened, abnormal and plaque, etc.) were not distinguished in the included literature, resulting in the inability to conduct subgroup analysis on the correlation between SUA and different types of CIMT abnormalities. Third, the analysis was also limited by the number of included studies and the quality of individual studies. We were unable to conduct an adequate combinatorial analysis during the subgroup analysis, and many other important factors affecting CIMT could not be analysed. Finally, unmeasured and residual confounding may result in confusion in relation to the conclusion. Given the limitations of our meta-analysis, further large-scale studies and sufficient samples are needed to demonstrate a convincing link between serum uric acid level and carotid intima-media thickness.

Conclusion

The results of the meta-analysis show that there is a relationship between serum uric acid level and carotid intima-media thickness in both healthy and diseased people, but the findings cannot show whether this is a causal relationship. At present, the research in this field mainly includes molecular and cell biology research and cross-sectional observational exploration. The conclusion of this study has great guiding significance for related research on risk factors for carotid intimal thickness thickening, suggesting that in the prevention of atherosclerosis, in addition to traditional elements, attention should be paid to the prevention and treatment of hyperuricaemia. The level of serum uric acid can be taken as an important reference basis. In clinical practice, early detection of serum uric acid should be considered, and an appropriate reduction in the serum uric acid level is necessary to prevent carotid intimal thickening. On this basis, cardio-cerebrovascular disease experts should advise their patients to consume a reasonable diet, develop good lifestyle habits, and prevent and avoid the formation of hyperuricaemia and carotid atherosclerosis.

Supporting information

S1 Appendix. Subgroup analysis of forest plots based on other risk factors for cardiovascular and cerebrovascular diseases.

(DOCX)

S2 Appendix. PRISMA checklist.

(DOC)

S1 Table. Summary of the included literature characteristics and key findings.

(DOCX)

S2 Table. Confounding factors in the 15 references included in the meta-analysis.

(DOCX)

Acknowledgments

We are grateful for all professors and colleagues for helping us during the current research.

Data Availability

All relevant data are within the manuscript and its Supporting Information files.

Funding Statement

This work was supported by the Chongqing Science and Technology Commission (cstc2018jscx-msybX003) and Chongqing Municipal Health and Health Committee (ZY201802121). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors received no specific funding for this work.

References

  • 1.Liu F, Du GL, Song N, Ma YT, Li XM, Gao XM, et al. Hyperuricemia and its association with adiposity and dyslipidemia in Northwest China: results from cardiovascular risk survey in Xinjiang (CRS 2008–2012). Lipids Health Dis. 2020;19(1):58 Epub 2020/04/03. 10.1186/s12944-020-01211-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Liu Y, Yan L, Lu J, Wang J, Ma H. A pilot study on the epidemiology of hyperuricemia in Chinese adult population based on big data from Electronic Medical Records 2014 to 2018. Minerva Endocrinol. 2020;45(2):97–105. Epub 2020/04/11. 10.23736/S0391-1977.20.03131-4 . [DOI] [PubMed] [Google Scholar]
  • 3.Dong X, Zhang H, Wang F, Liu X, Yang K, Tu R, et al. Epidemiology and prevalence of hyperuricemia among men and women in Chinese rural population: The Henan Rural Cohort Study. Mod Rheumatol. 2020;30(5):910–20. Epub 2019/08/24. 10.1080/14397595.2019.1660048 . [DOI] [PubMed] [Google Scholar]
  • 4.Liu R, Han C, Wu D, Xia X, Gu J, Guan H, et al. Prevalence of Hyperuricemia and Gout in Mainland China from 2000 to 2014: A Systematic Review and Meta-Analysis. Biomed Res Int. 2015;2015:762820 Epub 2015/12/08. 10.1155/2015/762820 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Chen-Xu M, Yokose C, Rai SK, Pillinger MH, Choi HK. Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey, 2007–2016. Arthritis Rheumatol. 2019;71(6):991–9. Epub 2019/01/09. 10.1002/art.40807 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Saeed S, Kanaya AM, Bennet L, Nilsson PM. Cardiovascular risk assessment in South and Middle-East Asians living in the Western countries. Pak J Med Sci. 2020;36(7):1719–25. Epub 2020/11/26. 10.12669/pjms.36.7.3292 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Moroni F, Ammirati E, Hainsworth AH, Camici PG. Association of White Matter Hyperintensities and Cardiovascular Disease: The Importance of Microcirculatory Disease. Circ Cardiovasc Imaging. 2020;13(8):e010460 Epub 2020/11/25. 10.1161/CIRCIMAGING.120.010460 . [DOI] [PubMed] [Google Scholar]
  • 8.Meng LB, Zou YF, Shan MJ, Zhang M, Qi RM, Yu ZM, et al. Computer-assisted prediction of atherosclerotic intimal thickness based on weight of adrenal gland, interleukin-6 concentration, and neural networks. J Int Med Res. 2020;48(1):300060519839625 Epub 2019/05/02. 10.1177/0300060519839625 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Zhang S, Wang Y, Cheng J, Huangfu N, Zhao R, Xu Z, et al. Hyperuricemia and Cardiovascular Disease. Curr Pharm Des. 2019;25(6):700–9. Epub 2019/04/10. 10.2174/1381612825666190408122557 . [DOI] [PubMed] [Google Scholar]
  • 10.Xu Y, Zhu J, Gao L, Liu Y, Shen J, Shen C, et al. Hyperuricemia as an independent predictor of vascular complications and mortality in type 2 diabetes patients: a meta-analysis. PLoS One. 2013;8(10):e78206 Epub 2013/11/10. 10.1371/journal.pone.0078206 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Cipolli JA, Ferreira-Sae MC, Martins RP, Pio-Magalhães JA, Bellinazzi VR, Matos-Souza JR, et al. Relationship between serum uric acid and internal carotid resistive index in hypertensive women: a cross-sectional study. BMC Cardiovasc Disord. 2012;12:52 Epub 2012/07/18. 10.1186/1471-2261-12-52 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Bae JS, Shin DH, Park PS, Choi BY, Kim MK, Shin MH, et al. The impact of serum uric acid level on arterial stiffness and carotid atherosclerosis: the Korean Multi-Rural Communities Cohort study. Atherosclerosis. 2013;231(1):145–51. Epub 2013/10/16. 10.1016/j.atherosclerosis.2013.08.017 . [DOI] [PubMed] [Google Scholar]
  • 13.Cho YS, Bae JH, Moon SH, Hyun SH, Choi JY, Kim BT, et al. Serum uric acid in asymptomatic adults is weakly associated with carotid artery FDG uptake but not intima-media thickness. J Nucl Cardiol. 2020;27(5):1537–46. Epub 2018/08/30. 10.1007/s12350-018-1424-3 . [DOI] [PubMed] [Google Scholar]
  • 14.Li LX, Wang AP, Zhang R, Li TT, Wang JW, Bao YQ, et al. Decreased urine uric acid excretion is an independent risk factor for chronic kidney disease but not for carotid atherosclerosis in hospital-based patients with type 2 diabetes: a cross-sectional study. Cardiovasc Diabetol. 2015;14:36 Epub 2015/04/19. 10.1186/s12933-015-0199-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Siemińska E, Sobczak P, Skibińska N, Sikora J. The differential role of uric acid—The purpose or cause of cardiovascular diseases? Med Hypotheses. 2020;142:109791 Epub 2020/05/21. 10.1016/j.mehy.2020.109791 . [DOI] [PubMed] [Google Scholar]
  • 16.Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1 Epub 2015/01/03. 10.1186/2046-4053-4-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Kaplowitz K, Bussel II, Honkanen R, Schuman JS, Loewen NA. Review and meta-analysis of ab-interno trabeculectomy outcomes. Br J Ophthalmol. 2016;100(5):594–600. Epub 2016/01/07. 10.1136/bjophthalmol-2015-307131 . [DOI] [PubMed] [Google Scholar]
  • 18.Borghi C, Agabiti-Rosei E, Johnson RJ, Kielstein JT, Lurbe E, Mancia G, et al. Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease. Eur J Intern Med. 2020;80:1–11. Epub 2020/08/03. 10.1016/j.ejim.2020.07.006 . [DOI] [PubMed] [Google Scholar]
  • 19.Zhang Bing, Kang Jie, Chen Xiaoming. Methods to Combine Standard Deviations of Different Subgroups in Meta-analysis. Zhongguo Xunzheng Yixue Zazhi. 2016;16(07):851–4 (in Chinese). [Google Scholar]
  • 20.Zhang Ranran. Association Between Carotid Atherosclerosis And Serum Uric Acid Level in middle-aged and elderly people. Qingdao university; 2018. (in Chinese). [Google Scholar]
  • 21.Zhang Hailing, Wang Haitao, Yang Wenhao, Cui Liufu, Zhang Jie, Jiang Xiaozhong. Relationship between Serum Uric Acid and Carotid Intima Media Thickness. Fujian Yike Daxue Xuebao. 2017;51(04):234–9(in Chinese). [Google Scholar]
  • 22.Zhang Zhigai. Relationship between serum uric acid and urinary microalbumin levels and carotid intimal disease in type 2 diabetes mellitus. Zhonghua Shiyong Yiyao Zazhi. 2013;8(06):45–6 (in Chinese). [Google Scholar]
  • 23.Yang Chunyu, Zhai Lihua, Lu Jun, Liang Xu. Relationship Between Serum Uric Acid Level and Carotid Atherosclerosis. Hebei Yixue. 2005;(06):552–3 (in Chinese). [Google Scholar]
  • 24.Antonini-Canterin F, Di Nora C, Pellegrinet M, Vriz O, La Carrubba S, Carerj S, et al. Effect of uric acid serum levels on carotid arterial stiffness and intima-media thickness: A high resolution Echo-Tracking Study. Monaldi Arch Chest Dis. 2019;89(1). Epub 2019/04/11. 10.4081/monaldi.2019.1007 . [DOI] [PubMed] [Google Scholar]
  • 25.Li Q, Yang Z, Lu B, Wen J, Ye Z, Chen L, et al. Serum uric acid level and its association with metabolic syndrome and carotid atherosclerosis in patients with type 2 diabetes. Cardiovasc Diabetol. 2011;10:72 Epub 2011/08/06. 10.1186/1475-2840-10-72 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Chang CC, Wu CH, Liu LK, Chou RH, Kuo CS, Huang PH, et al. Association between serum uric acid and cardiovascular risk in nonhypertensive and nondiabetic individuals: The Taiwan I-Lan Longitudinal Aging Study. Sci Rep. 2018;8(1):5234 Epub 2018/03/29. 10.1038/s41598-018-22997-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Kumral E, Karaman B, Orman M, Kabaroglu C. Association of uric acid and carotid artery disease in patients with ischemic stroke. Acta Neurol Scand. 2014;130(1):11–7. Epub 2013/12/10. 10.1111/ane.12208 . [DOI] [PubMed] [Google Scholar]
  • 28.Kawamoto R, Tomita H, Oka Y, Kodama A, Ohtsuka N, Kamitani A. Association between uric acid and carotid atherosclerosis in elderly persons. Intern Med. 2005;44(8):787–93. Epub 2005/09/15. 10.2169/internalmedicine.44.787 . [DOI] [PubMed] [Google Scholar]
  • 29.Caliskan M, Guven A, Ciftci O, Ozulku M, Gunday M, Barutcu I. Serum uric acid and carotid artery intima media thickness in patients with masked hypertension. Acta Cardiol. 2014;69(4):417–23. Epub 2014/09/04. 10.1080/ac.69.4.3036658 . [DOI] [PubMed] [Google Scholar]
  • 30.Asicioglu E, Kahveci A, Arikan H, Koc M, Tuglular S, Ozener C. Fibroblast Growth Factor–23 Levels Are Associated With Uric Acid But Not Carotid Intima Media Thickness in Renal Transplant Recipients. Transplantation Proceedings. 2014;46(1):180–3. 10.1016/j.transproceed.2013.10.043 [DOI] [PubMed] [Google Scholar]
  • 31.Acikgoz N, Ermis N, Yagmur J, Muezzinoglu K, Karakus Y, Cansel M, et al. Uric acid level and its association with carotid intima-media thickness in patients with cardiac syndrome X. Med Princ Pract. 2012;21(2):115–9. Epub 2011/11/15. 10.1159/000332583 . [DOI] [PubMed] [Google Scholar]
  • 32.Tavil Y, Kaya MG, Oktar SO, Sen N, Okyay K, Yazici HU, et al. Uric acid level and its association with carotid intima-media thickness in patients with hypertension. Atherosclerosis. 2008;197(1):159–63. Epub 2007/04/10. 10.1016/j.atherosclerosis.2007.03.008 . [DOI] [PubMed] [Google Scholar]
  • 33.Wu SS, Kor CT, Chen TY, Liu KH, Shih KL, Su WW, et al. Relationships between Serum Uric Acid, Malondialdehyde Levels, and Carotid Intima-Media Thickness in the Patients with Metabolic Syndrome. Oxid Med Cell Longev. 2019;2019:6859757 Epub 2019/11/07. 10.1155/2019/6859757 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Arévalo-Lorido JC, Carretero-Gómez J, Robles Pérez-Monteoliva NR. Association between serum uric acid and carotid disease in patients with atherosclerotic acute ischemic stroke. Vascular. 2019;27(1):19–26. Epub 2018/09/13. 10.1177/1708538118797551 . [DOI] [PubMed] [Google Scholar]
  • 35.Harada M, Fujii K, Yamada Y, Tsukada W, Tsukada M, Hashimoto K, et al. Relationship between serum uric acid level and vascular injury markers in hemodialysis patients. Int Urol Nephrol. 2020;52(8):1581–91. Epub 2020/06/20. 10.1007/s11255-020-02531-w . [DOI] [PubMed] [Google Scholar]
  • 36.Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA. Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2010;62(2):170–80. Epub 2010/03/02. 10.1002/acr.20065 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Willeit P, Tschiderer L, Allara E, Reuber K, Seekircher L, Gao L, et al. Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk: Meta-Analysis of 119 Clinical Trials Involving 100 667 Patients. Circulation. 2020;142(7):621–42. Epub 2020/06/18. 10.1161/CIRCULATIONAHA.120.046361 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Hong Q, Wang L, Huang Z, Feng Z, Cui S, Fu B, et al. High Concentrations of Uric Acid and Angiotensin II Act Additively to Produce Endothelial Injury. Mediators Inflamm. 2020;2020:8387654 Epub 2020/06/23. 10.1155/2020/8387654 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Gertler MM, Garn SM, Levine SA. Serum uric acid in relation to age and physique in health and in coronary heart disease. Ann Intern Med. 1951;34(6):1421–31. Epub 1951/06/01. 10.7326/0003-4819-34-6-1421 . [DOI] [PubMed] [Google Scholar]
  • 40.Mallamaci F, Testa A, Leonardis D, Tripepi R, Pisano A, Spoto B, et al. A genetic marker of uric acid level, carotid atherosclerosis, and arterial stiffness: a family-based study. Am J Kidney Dis. 2015;65(2):294–302. Epub 2014/10/11. 10.1053/j.ajkd.2014.07.021 . [DOI] [PubMed] [Google Scholar]
  • 41.Ishizaka N, Ishizaka Y, Toda E, Nagai R, Yamakado M. Association between serum uric acid, metabolic syndrome, and carotid atherosclerosis in Japanese individuals. Arterioscler Thromb Vasc Biol. 2005;25(5):1038–44. Epub 2005/03/05. 10.1161/01.ATV.0000161274.87407.26 . [DOI] [PubMed] [Google Scholar]
  • 42.Li L-X, Dong X-H, Li M-F, Zhang R, Li T-T, Shen J, et al. Serum uric acid levels are associated with hypertension and metabolic syndrome but not atherosclerosis in Chinese inpatients with type 2 diabetes. J Hypertens. 2015;33(3):482–90; discussion 90. 10.1097/HJH.0000000000000417 . [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Giuseppina Novo

6 Nov 2020

PONE-D-20-28226

Meta-analysis of the correlaion between serum uric acid level and carotid intima-media thickness

PLOS ONE

Dear Dr. Mao,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Dec 21 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Giuseppina Novo

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please provide the following information in your Methods section relating to the search terms used for the systematic review. Please also amend the PRISMA checklist to display the corresponding page numbers of each checklist item.

3. Thank you for stating the following financial disclosure: [NO STATEMENT PROVIDED]

At this time, please address the following queries:

  1. Please clarify the sources of funding (financial or material support) for your study. List the grants or organizations that supported your study, including funding received from your institution.

  2. State what role the funders took in the study. If the funders had no role in your study, please state: “The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

  3. If any authors received a salary from any of your funders, please state which authors and which funders.

  4. If you did not receive any funding for this study, please state: “The authors received no specific funding for this work.”

*Please include your amended statements within your cover letter; we will change the online submission form on your behalf.*

4. Thank you for stating the following in your Competing Interests section: [NO STATEMENT PROVIDED]

A. Please complete your Competing Interests statement to state any Competing Interests. If you have no competing interests, please state "The authors have declared that no competing interests exist.", as detailed online in our guide for authors at http://journals.plos.org/plosone/s/submit-now

b. This information should be included in your cover letter; we will change the online submission form on your behalf.

Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: http://journals.plos.org/plosone/s/competing-interests

5. Please amend either the title on the online submission form (via Edit Submission) or the title in the manuscript so that they are identical.

6. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Yes

Reviewer #3: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: I Don't Know

Reviewer #2: Yes

Reviewer #3: No

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

Reviewer #2: Yes

Reviewer #3: No

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: I think I made a mistake accepting the revision of this article whose validity is substantially linked to the soundness of its statistical approach that goes, unfortunately, beyond my level knowledge. Topic is certainly interesting but, given the ambiguity about this subject, as reported in the literature, I think that a sound statistical check (that goes beyond my capacity) is necessary.

There are a few grammatical errors in the text. The style of references is not uniform across the list

Reviewer #2: In this paper, authors analyze through meta-analysis the relationship between serum uric acid level and carotid

intimal thickness.The paper is well designed and the conclusion, such as that there is a significant correlation between serum uric acid level and carotid intima-media thickness, and a high concentration of serum uric acid is related to carotid artery intima-media thickness are beliavable.

I would suggest some revisions as follows:

- in the abstract, I suggest to better explicate these sentence that was repeated: "Meta-analysis showed that carotid intimal thickness in the high uric acid group was significantly higher than that in the control group [...] The results showed that the carotid intimal thickness of the high uric acid group was still significantly higher than that of the control group, and the difference was statistically significant".

- the 15 articles selected for the meta-analysis have not been cited; please add the references of these articles to allow readers to know them, maybe it would be added in the Table 1;

- Figure 5 contains a mistake in the author "Francesco Antonini-Canterin" that was wrongly written.

Reviewer #3: This is a meta-analysis study focus on the relationship between serum uric acid level the carotid intima-media thickness. Previous studies have shown that CIMT is the main risk factor and main pathophysiological basis of ASCVD. However, the correlation between hyperuricemia and ASCVD is still controversial. In current study contain some serious flaws and some concerns need to be addressed,

1. CIMT determination uses different B-ultrasound equipment in different research centers, and uses different operating procedures, how to evaluate the differences between centers?

2. The population included in the study is biased, and there are high-risk groups of ASCVD such as diabetes, which requires further subgroup analysis.

3. Other influencing factors of ASCVD such as blood lipid level, BP, medication status, BMI, etc. may be alternative in different studies. This will ultimately affect the value of CMIT and should be included in the analysis.

4. The mechanism of the effect of hyperuricemia on CIMT and even atherosclerosis is not sufficiently explained in the discussion section, and further elucidation is needed.

5. The normal value of CMIT is generally considered to be below 1.0mm, 1.0-1.2mm is considered to be thickened, and 1.2mm or more is considered abnormal. Can the CIMT value be subdivided into different subgroups for analysis and discuss the relationship between hyperuricemia and the abnormal rate of CMIT?

6. Professional language editing must be done prior to re-submission.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: Yes: Concetta Di Nora

Reviewer #3: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2021 Feb 11;16(2):e0246416. doi: 10.1371/journal.pone.0246416.r002

Author response to Decision Letter 0


9 Dec 2020

Editor:

*Any new text in the revised manuscript has been noted below in bold font.

1. In accordance with PLOS ONE’s style requirements, we have updated the file names and manuscript title, as well as the references.

2. Search terms used for the systematic review have been added to the Methods section, and PRISMA checklist has been updated in accordance with PLOS guidelines.

3. Statements of funding information have been included at the cover letter.

4. Description of competing Interests has been included at the cover letter.

5. The title in the manuscript has been modified according to the title of the online submission system.

6. Supporting Information files have been included at the end of the manuscript, and in-text citations have been updated in accordance with PLOS guidelines.

Reviewer #1:

We thank Reviewer #1 for the significant feedback. We strongly agree with the reviewer's opinion that a statistical check should be conducted on ambiguous subjects, which is also the purpose of our meta-analysis: we conducted a comprehensive analysis of the existing research with a statistical review to expand the sample size and better explore the correlation between serum uric acid level and carotid intimal thickness.

The revised article was submitted after careful language review, and the style of references has been uniformly modified in accordance with PLOS guidelines. Thanks for your correction!

Reviewer #2:

We thank Reviewer #2 for the important suggestion to explicate the sentence that was repeated. The second half of the repeated part in the abstract is actually the conclusion of the subgroup analysis. We have made the following corrections (Abstract, lines 17-26):

“Meta-analysis showed that CIMT in the high uric acid group was significantly higher than that in the control group (SMD = 0.53, 95% CI: [0.38, 0.68]), and the difference was significant (z = 6.98, P < 0.00001). The heterogeneity among the 15 articles was obvious (I2 = 89%, P < 0.00001). Subgroup analysis by disease status illustrated a positive relationship between SUA and CIMT in healthy people and people with diseases. SUA was shown to be positively correlated with CIMT in people aged 45-60 years and ≥60 years by subgroup analysis by age. SUA was also found to be positively correlated with CIMT in a population with BMI>24 kg/m2 by subgroup analysis by BMI. In addition, subgroup analysis of other risk factors for CIMT, including TC, SBP, DBP, triglycerides, and LDL-C, all showed a positive correlation between SUA and CIMT.”

We thank Reviewer #2 for the suggestion to add the 15 articles selected for the meta-analysis to the references. We have added these 15 articles to the reference section ([20-34]) and added the "Author" column in Table 1, with references to the corresponding literature after the author's name.

The mistake in Figure 5 has been corrected.

Reviewer #3:

We thank reviewer #3 for the extensive feedback, and we have incorporated most of it. Based on that, we think our paper has improved to a great extent. It also became more comprehensible for the reader. Thank you.

1. We would like to thank the Reviewer for raising the question of different instruments and procedures for measuring CIMT between studies. In the process of measurement, random error is inevitable due to different operators and instruments. However, the measurement methods of each research centre are strictly in accordance with the medical testing guidelines and consensus [1-4] and control the error within the acceptable range. Thus, the difference is subtle.

2. We agree with the Reviewer that further subgroup analysis is necessary. We conducted a subgroup analysis between healthy people and people at high risk of cardiovascular and cerebrovascular disease. The results are shown in Table 2, and the heterogeneity of subgroups is shown in Table 3. The following text was added to the Results section (Results, lines 156-164):

“Because the correlation between SUA and CIMT is affected by population characteristics and may be affected by other risk factors for CIMT, we conducted subgroup analyses. Initially, we divided the population into two groups and found that CIMT levels were higher in the high uric acid group than in the control group, both in healthy people and in people with diseases. (Healthy people: SMD = 0.29, 95% CI: [0.17, 0.42]; people with diseases: SMD = 0.73, 95% CI: [0.52, 0.95]). The differences were statistically significant (P < 0.00001), as shown in Fig 4, which meant that SUA levels were positively correlated with CIMT. In addition, the heterogeneity of the two subgroups decreased but was still significant (I2 = 78%, P = 0.0001; I2 = 73%, P = 0.0005).”

We also added the results of subgroup analysis to the Abstract (Abstract, lines 20-21):

“Subgroup analysis by disease status illustrated a positive relationship between SUA and CIMT in healthy people and people with diseases.”

3. We strongly agree with the opinion that confounding factors should be considered when researching the correlation between SUA and CIMT. We have added some subgroup analyses of cardiovascular and cerebrovascular disease risk factors that may influence CIMT thickness (age, BMI, TC, SBP, DBP, LDL-C and triglyceride) and added the following content to the Results section (Results, lines 165-173):

“To further control for confounders, we performed an age-based subgroup analysis and found a positive correlation between SUA and CIMT in people aged 45-60 years and ≥60 years (Fig 4), but no correlation was found in people between the ages of 18 and 45. We also performed a subgroup analysis based on BMI. The SUA level was significantly positively correlated with CIMT in people with BMI>24 kg/m2. In addition, we performed subgroup analysis on other risk factors for CIMT: TC, SBP, DBP, triglycerides and LDL-C (the forest plots are shown in S1 Appendix). The results showed that the carotid intimal thickness of the high uric acid group was higher than that of the control group, and the difference was statistically significant (Table 2). The heterogeneity of each subgroup is shown in Table 3.”

We also added the results of subgroup analysis to the Abstract (Abstract, lines 22-26):

“SUA was shown to be positively correlated with CIMT in people aged 45-60 years and ≥60 years by subgroup analysis by age. SUA was also found to be positively correlated with CIMT in a population with BMI>24 kg/m2 by subgroup analysis by BMI. In addition, subgroup analysis of other risk factors for CIMT, including TC, SBP, DBP, triglycerides, and LDL-C, all showed a positive correlation between SUA and CIMT.”

However, because the number of included studies was limited and the confounders included in each study were not exactly the same (we added the confounders of each article to S2 Table), some confounders were included in too few articles. We were unable to conduct an adequate combinatorial analysis during the subgroup analysis, nor were we able to analyse many other important factors that might affect CIMT, which may result in confusion in relation to the conclusion. This is also one of the limitations of our research. We have added this information to the limitations of the article (Discussion, lines 276-279):

“Third, the analysis was also limited by the number of included studies and the quality of individual studies. We were unable to conduct an adequate combinatorial analysis during the subgroup analysis, and many other important factors affecting CIMT could not be analysed.”

4. We appreciate the suggestion by Reviewer #3 to further discuss the mechanisms of hyperuricaemia in CIMT and atherosclerosis. We have added to the Discussion section a description of how hyperuricaemia affects CIMT and atherosclerosis (Discussion, lines, 204-223):

“The destruction of the vascular wall and endothelial cell function are direct causes of atherosclerosis. As an end product of purine metabolism in humans and higher primates, uric acid can damage the integrity of the vascular surface and affect the function of endothelial cells through direct or indirect effects on the vascular endothelium. The mechanism of this process is as follows: uric acid can promote the proliferation and migration of vascular smooth muscle cells and even lead to vascular remodelling, affecting its normal function. When the concentration of uric acid in the blood reaches a certain level, it will deposit into the tissue in the form of urate crystals and damage the vascular endothelium. The occurrence of hyperuricaemia aggravates abnormalities in metabolites and affects the vascular endothelium and haemodynamics [23]. Oxidative stress is the key link in endothelial dysfunction caused by hyperuricaemia and is related to the increased risk of cardiovascular and cerebrovascular disease [39]. However, there is another effect of uric acid level on carotid atherosclerosis. When blood vessels are in the atherosclerotic state, the pro-oxidant state will inactivate some superoxide dismutases (e.g., NOS1 and NOS3, etc.) and reduce the scavenging of free radicals in blood vessels, thus increasing the oxygen level [40]. Uric acid protects the activity of these inactivated enzymes and may counteract the harmful effects of hyperuricaemia in some areas of the vascular system [26]. Because uric acid is generally considered to have more harmful than protective effects, it is considered to be a risk factor for CIMT and atherosclerosis [36, 37, 42], but the clinical relevance of the two has been controversial.”

5. We thank Reviewer #3 very much for posing this important question, which is what we want to solve. However, most of the literature measured only CIMT thickness and did not classify the population according to the status of CIMT (thickened, abnormal or plaque), so we failed to explore the relationship between hyperuricaemia and the abnormal rate of CIMT through subgroup analysis. We have added the following to illustrate these limitations in the discussion section (Discussion, lines 273-276):

“Second, similarly, different conditions of CIMT (thickened, abnormal and plaque, etc.) were not distinguished in the included literature, resulting in the inability to conduct subgroup analysis on the correlation between SUA and different types of CIMT abnormalities.”

6. Professional language editing has been completed.

Reference:

1. Management of Atherosclerotic Carotid and Vertebral Disease: 2017 Clinical Practice Guidelines of the European Society for Vascular Surgery (ESVS):http://sr.xingshulin.com/view/guide.html?id=13703&share_ticket=code%3D-1%26version%3D7.16.0%26os%3Da

2. Saba L, Yuan C, Hatsukami TS, Balu N, Qiao Y, DeMarco JK, et al. Carotid Artery Wall Imaging: Perspective and Guidelines from the ASNR Vessel Wall Imaging Study Group and Expert Consensus Recommendations of the American Society of Neuroradiology. AJNR Am J Neuroradiol. 2018;39(2):E9-e31. Epub 2018/01/13. doi: 10.3174/ajnr.A5488. PubMed PMID: 29326139; PubMed Central PMCID: PMCPMC7410574.

3. Xiaoying Li, Heng Guan, Tingshu Yang, Wei Guo, Shuxia Wang. Chinese experts suggest the diagnosis and treatment of atherosclerotic diseases in the limbs of the elderly (2012). Chinese Journal of Geriatrics. 2013;(02):121-31.(in Chinese)

4. Chinese guidelines for interventional diagnosis and treatment of carotid artery stenosis: http://sr.xingshulin.com/view/guide.html?id=7150&share_ticket=code%3D-1%26version%3D7.16.0%26os%3Da

Attachment

Submitted filename: Response to Reviewers.docx

Decision Letter 1

Giuseppina Novo

8 Jan 2021

PONE-D-20-28226R1

Meta-analysis of the correlation between serum uric acid level and carotid intima-media thickness

PLOS ONE

Dear Dr. Mao,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Particularly revise the discussion according to one of the reviewers suggestions. Afterwards there are no more comments to be addressed.

Please submit your revised manuscript by Feb 22 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Giuseppina Novo

Academic Editor

PLOS ONE

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #2: All comments have been addressed

Reviewer #3: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #2: Yes

Reviewer #3: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #2: Yes

Reviewer #3: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: Yes

Reviewer #3: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: Yes

Reviewer #3: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: In this paper, authors analyze through meta-analysis the relationship between serum uric acid level and carotid intimal thickness. The paper is well designed and the conclusion, such as that there is a significant correlation

between serum uric acid level and carotid intima-media thickness, and a high concentration of serum uric acid is related to carotid artery intima-media thickness are beliavable.

All the previous concerns have been adequately addressed by the authors.

Reviewer #3: The discussion could be more concise and highlight its clinical significance, in addition, there is a little no more revision needed.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #2: Yes: Concetta Di Nora

Reviewer #3: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2021 Feb 11;16(2):e0246416. doi: 10.1371/journal.pone.0246416.r004

Author response to Decision Letter 1


13 Jan 2021

Editor:

*Any new text in the revised manuscript has been noted below in bold font.

The Discussion section has been modified according to the suggestions of reviewers.

RESPONSE TO REVIEWER’S COMMENTS:

Reviewer #3: The discussion could be more concise and highlight its clinical significance, in addition, there is a little no more revision needed.

Reply: We appreciate the excellent observation from Reviewer #3 regarding the Discussion section. We adopted the suggestions of reviewers, revised the discussion and added the following contents to highlight the clinical significance (Discussion, lines 244-251):

“Therefore, this study revealed that a high level of SUA may be a predictor of atherosclerosis, and strengthening the control of serum uric acid levels in early prevention is helpful to reduce the risk of atherosclerosis. These findings proved that the rising level of SUA could pose an increased risk of cardiovascular and cerebrovascular diseases, provided a potential therapeutic target and new ideas for further clinical researches. It was suggested that decreasing level of uric acid could be an adjunctive therapy for cardiovascular and cerebrovascular diseases, and the atherosclerosis diagnosis and treatment also could be supported by testing the level of SUA in clinic.”

Attachment

Submitted filename: Response to Reviewers.docx

Decision Letter 2

Giuseppina Novo

20 Jan 2021

Meta-analysis of the correlation between serum uric acid level and carotid intima-media thickness

PONE-D-20-28226R2

Dear Dr. Mao,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Giuseppina Novo

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #2: All comments have been addressed

Reviewer #3: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #2: (No Response)

Reviewer #3: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #2: (No Response)

Reviewer #3: N/A

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: (No Response)

Reviewer #3: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: (No Response)

Reviewer #3: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: ----------------------------------------------------------------------------------------------------

Reviewer #3: The author has rigorously answered the reviewer's questions and made corresponding modifications. Now it could be accepted for publication.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #2: Yes: CONCETTA DI NORA

Reviewer #3: No

Acceptance letter

Giuseppina Novo

22 Jan 2021

PONE-D-20-28226R2

Meta-analysis of the correlation between serum uric acid level and carotid intima-media thickness

Dear Dr. Mao:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Professor Giuseppina Novo

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Appendix. Subgroup analysis of forest plots based on other risk factors for cardiovascular and cerebrovascular diseases.

    (DOCX)

    S2 Appendix. PRISMA checklist.

    (DOC)

    S1 Table. Summary of the included literature characteristics and key findings.

    (DOCX)

    S2 Table. Confounding factors in the 15 references included in the meta-analysis.

    (DOCX)

    Attachment

    Submitted filename: Response to Reviewers.docx

    Attachment

    Submitted filename: Response to Reviewers.docx

    Data Availability Statement

    All relevant data are within the manuscript and its Supporting Information files.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES